Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT-GBM Trial (GlobeNewswire) - Jul 22, 2021 - "Plus Therapeutics, Inc...announced the first patient in the eighth cohort of the Phase 1 dose escalation ReSPECT™-GBM clinical trial for recurrent glioblastoma (rGBM) has been successfully treated. The present cohort implements a 40% increase in volume (12.3 milliliters) and total radioactivity (31.2 millicuries) from the previous cohort...‘We plan to provide an update on the trial in the fourth quarter of 2021.'"
P1 data • Trial status • Glioblastoma • Oncology
|